News

IMI-money for intelli-research
Enlarge image

FundingEUUKSwitzerland

IMI-money for intelli-research

06.12.2012 - The Innovative Medicines Initiative funds seven new projects with a total of €237m. The main focus is on drug development and data integration.

The exciting field of stem cell research and the seemingly insurmountable ranges of biodata are undergoing in-depth analyses over the next few years. The unifying context behind these projects is the mission to improve drug development. As announced on 5 December, the Innovative Medicines Alliance (IMI) will spend in total more than €237m on research topics ranging from stem cells (STEMBANCC), data integration (EMIF and eTRIKS) and ‚green’ drug development (CHEM21) to drug-target-interaction (K4DD), drug uptake into (ORBITO) and drug distribution within (COMPACT) the body.

Within STEMBANCC ten pharmaceutical companies and 23 academic institutions from 11 countries will develop 1,500 human induced pluripotent stem cell lines from about 500 patients to study diseases and test drugs for safety and efficacy. Swiss pharma Roche initiated the project, which will be coordinated by the University of Oxford (UK). Using cells isolated from patients, the scientists hope to identify the genes and mechanisms that play a role in diseases of the nervous system such as peripheral pain, migraine, autism, schizophrenia, bipolar disorders, dementiae and diabetes. Taken together, IMI now finances 37 projects with a volume of almost €800m.

It was just in June this year, that the last current IMI projects were presented. The €215m they received is only 91% of the sum the new projects of the 4th wave will get. The IMI, a joint venture of the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) is Europe’s biggest public-private partnership to accelerate the development of better drugs. Currently, applicants can bid for the 8th call „Combating Antibiotic Resistance“. The calls five to seven have already been closed for submission of Expressions of Interest (EoI) and are in different stages of processing.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/imi-money-for-intelli-research.html

FinancingPoland

24.03.2015 Poland has announced the closing of a new venture capital fund at US$42m (€32m). The fund, which is the first of its kind in Poland, is dedicated to the Life Sciences with a strong connection to Central and Eastern Europe.

BioeconomyFranceSwedenGermanyNetherlandsFinland

23.03.2015 A BASF-led consortium aims to decrease bio-based production costs using industrial biotechnology. The Horizon2020 funded consortium is the sixth project of the SPIRE Public Private Partnership and has a budget of €14m.

Stock MarketsFranceSwedenUKNorwayIreland

20.03.2015 There are no signs of inertia creeping into the European biotech industry this spring. A total of eight IPOs are set to go public by the end of the year’s first quarter.

FinancingUKEU

17.03.2015 Pharma giants GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) will be key collaborators in a new global fund for dementia research to address the rising threat posed by dementia and Alzheimer’s disease.

FinancingFranceDenmarkSwedenGermany

19.03.2015 French venture capital firm Seventure Partners has raised a further €25m for its microbiome-focused Health for Life Capital Fund. It now stands at €100m.

EventsFranceEUSwitzerlandUKGermany

12.03.2015 With around 1,400 companies and 2,400 participants, the springtime counterpart of BIO-Europe enjoyed a successful premiere in France this year. The overall mood of the European biotech industry was positive, and the French hosts in particular reported new initiatives.

M&ABelgium

11.03.2015 Belgian cell-based therapeutics developer and CMO MaSTherCell SA has been acquired by US biotech Orgenesis Inc. for €23m.

FinancingGermany

10.03.2015 The Gates Foundation has dipped into its purse to bring infectious diseases vaccines to the poorest countries. German vaccine specialist CureVac is set to receive US$52m for their mRNA platform technology.

Stock MarketsIrelandUK

05.03.2015 The IPO wave in the biotech sector shows no signs of slowing down. An Irish life sciences fund set up by former Elan executives plans to raise €325m with its IPO, whilst Summit Therapeutics has announced its IPO pricing of US$34m on Nasdaq.

LicencingDenmark

05.03.2015 Bavarian Nordic is outlicensing its Phase 3 prostate cancer immunotherapy Prostvac to pharma heavyweight Bristol Myers Squibb for a tidy €881m.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS1.54 CHF14.07%
  • SYNGENTA329.00 CHF0.27%
  • 4SC0.84 EUR0.00%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • BASILEA110.00 CHF-2.65%
  • ACTELION114.70 CHF-1.88%

TOP

  • CYTOS1.54 CHF352.9%
  • MEDIGENE13.50 EUR217.6%
  • FORMYCON26.00 EUR55.7%

FLOP

  • WILEX2.92 EUR-14.9%
  • BASILEA110.00 CHF-10.0%
  • MORPHOSYS70.55 EUR-5.6%

TOP

  • SANTHERA95.40 CHF2346.2%
  • WILEX2.92 EUR386.7%
  • FORMYCON26.00 EUR273.6%

FLOP

  • CYTOS1.54 CHF-49.7%
  • 4SC0.84 EUR-37.3%
  • THERAMETRICS0.07 CHF-36.4%

No liability assumed, Date: 26.03.2015